Glucocorticoids: Clinical Trials

128 trials of Glucocorticoids, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

50 completed, 33 unknown, 20 recruiting, 10 terminated. 37 Phase 2, 35 Phase 4, 23 Not applicable, 23 Phase 3, 9 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 237Completed 18, Recruiting 6, Unknown 5, Not yet recruiting 4, Active not recruiting 2, Terminated 2
Phase 435Unknown 13, Completed 11, Recruiting 6, Terminated 3, Active not recruiting 1, Withdrawn 1
Not applicable23Completed 9, Unknown 5, Recruiting 4, Not yet recruiting 3, Terminated 2
Phase 323Completed 11, Unknown 4, Terminated 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1
Phase 19Completed 6, Not yet recruiting 2, Unknown 1
Early Phase 12Active not recruiting 1, Unknown 1

Follow Glucocorticoids: new trials by email Literature Review of Glucocorticoids trials Research Report on Glucocorticoids

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy
Phase 4RecruitingSarepta Therapeutics, Inc.202026-11-302026-11-12
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome
Phase 2RecruitingNovartis Pharmaceuticals1202026-10-302026-11-09
Autologous Circulating Extracellular Vesicles for Total-Type Sudden Sensorineural Hearing Loss
autologous circulating extracellular vesicles, Glucocorticoids - Sudden Sensorineural Hearing Loss (SSNHL)
Phase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University1462026-09-152026-10-16
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV)
Phase 2RecruitingChinese PLA General Hospital202026-08-212026-09-15
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Momelotinib, Glucocorticoids, Placebo - VEXAS Syndrome
Phase 2 / Phase 3Not yet recruitingGlaxoSmithKline1362026-08-052026-06-01
1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study
IV glucocorticoid and antihistamine, IV glucocorticoid and antihistamine (standard of care) - Allergic Reaction to Contrast Media, Hypersensitivity Reaction
Not applicableNot yet recruitingPaul Peng, MD PhD MSCR5402026-06-012026-02-19
Bosentan in the Treatment of Giant Cell Arteritis
Bosentan, Glucocorticoids - Giant Cell Arteritis (GCA)
Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris402026-06-012026-05-06
Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares
Glucocorticoid (GC) - Rheumatoid Arthritis (RA)
Phase 4RecruitingSunnybrook Health Sciences Centre2202026-04-012026-04-13
A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia
Glucocorticoids - Autoimmune Hemolytic Anemia (AIHA)
Not applicableNot yet recruitingChen Miao2162026-04-012026-04-08
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase 2RecruitingNanjing University School of Medicine502025-12-082026-03-12
RCT of Tocilizumab for Anti-MDA5+DM
Tocilizumab, Standard medical treatment - Dermatomyositis
Not applicableRecruitingPeking Union Medical College Hospital1102025-11-012026-01-29
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV)
Phase 1 / Phase 2Not yet recruitingChao Ji1002025-10-012024-10-29
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Rilzabrutinib, Placebo, Glucocorticoid - Immunoglobulin G4 Related Disease
Phase 3RecruitingSanofi1242025-09-262026-10-20
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Phase 1 / Phase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang University622025-09-082025-09-08
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies
Phase 4RecruitingShanghai Changzheng Hospital962025-04-152025-09-03
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies
Phase 4RecruitingShanghai Changzheng Hospital642025-04-102025-09-03
A Single-center Study of CM313 in Patients With Pemphigus
CM313 injection, glucocorticoids - Pemphigus
Not applicableNot yet recruitingSichuan Provincial People's Hospital202025-04-012025-04-01
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV)
Phase 2Active not recruitingNovartis Pharmaceuticals1262025-03-132026-09-04
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Glucocorticoid Effect - Osteoporosis, Osteoporosis, Steroid Induced
RecruitingDiakonhjemmet Hospital1602025-01-012026-08-19
Efficacy and Safety of Telitacicept in IgAN
Telitacicept 240mg, Glucocorticoid - IgA Nephropathy (IgAN), Kidney Diseases
Not applicableRecruitingRuijin Hospital1182024-12-062025-01-01

Showing 20 of 128. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (10)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9)  ·  Granulomatosis with Polyangiitis (8)  ·  Glomerulonephritis, Membranous (5)  ·  Microscopic Polyangiitis (5)  ·  Recurrence (5)  ·  Vasculitis (5)  ·  Aspergillosis, Allergic Bronchopulmonary (4)  ·  Giant Cell Arteritis (4)  ·  Graves Ophthalmopathy (4)  ·  Immunoglobulin G4-Related Disease (3)  ·  Lung Diseases, Interstitial (3)  ·  Lupus Erythematosus, Systemic (3)  ·  Lupus Nephritis (3)  ·  Prostatic Neoplasms (3)

Sponsors

Peking Union Medical College Hospital (5)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (4)  ·  Institute of Hematology & Blood Diseases Hospital, China (3)  ·  Beijing Tongren Hospital (2)  ·  Chinese SLE Treatment And Research Group (2)  ·  Huashan Hospital (2)  ·  Insel Gruppe AG, University Hospital Bern (2)  ·  Janssen Research & Development, LLC (2)  ·  Jawaharlal Institute of Postgraduate Medical Education & Research (2)  ·  Massachusetts General Hospital (2)  ·  Medical University of South Carolina (2)  ·  Medical University of Vienna (2)  ·  Nanfang Hospital, Southern Medical University (2)  ·  Northwestern University (2)  ·  Novartis Pharmaceuticals (2)

Countries

China (52)  ·  United States (30)  ·  United Kingdom (12)  ·  France (10)  ·  Italy (10)  ·  Canada (9)  ·  Germany (9)  ·  Spain (8)  ·  Japan (7)  ·  Czechia (6)  ·  Denmark (6)  ·  India (6)  ·  Netherlands (6)  ·  Belgium (5)  ·  Sweden (5)

Top investigators

David Jayne, MD (2)  ·  Dong-Xin Wang, MD, PhD (2)  ·  Eric M Graham, MD (2)  ·  Luo Zhang (2)  ·  Peter A Merkel, MD, MPH (2)  ·  Ritesh Agarwal, MD, DM (2)  ·  Vir S Negi, DM (2)  ·  Ana D Fernandes, MA (1)  ·  Anja Pfaff, PhD (1)  ·  Barry Simon, MD (1)

Results publications

PMID 39425055, PMID 10068416, PMID 10517721, PMID 10683005, PMID 11334386, PMID 12727961, PMID 12826640, PMID 16221103, PMID 16622259, PMID 17332971, PMID 17923793, PMID 18000630, PMID 18421188, PMID 18535733, PMID 19138419, PMID 19337012, PMID 20054700, PMID 20478449, PMID 21510801, PMID 21802835, PMID 22252942, PMID 22619349, PMID 22925653, PMID 23227861, PMID 23587468, PMID 23870160, PMID 24203065, PMID 24694337, PMID 26585431, PMID 26952547, PMID 27013022, PMID 27117874, PMID 27924855, PMID 28246067, PMID 28388956, PMID 28945869, PMID 29195618, PMID 29247107, PMID 29331473, PMID 29961816, PMID 30561849, PMID 31132016, PMID 31206501, PMID 31260678, PMID 31668569, PMID 31671877, PMID 32053298, PMID 32162821, PMID 32374395, PMID 32392512

NIH funding

2016 (2), 2025 (2), R01HL115041 (2), 2009 (1), 2017 (1), 2018 (1), 2023 (1), R01HL112968 (1), R37HL068546 (1), U54AR057319 (1)